New Treatment For Triple Negative Breast Cancer

New treatment for triple negative breast cancer - In triple-negative breast cancer (TNBC), cancer cells do not contain estrogen, progesterone, or HER2 receptors. ( Triple negative breast cancer treatment ) This type of breast cancer is usually invasive and usually begins with a breast tube. Healthy breast cells contain hormones estrogen and progesterone receptors. They include a protein receptor called HER2 that stimulates normal cell proliferation.

Two out of three women with breast cancer have cells that contain estrogen and progesterone receptors, and about 20-30% of breast cancer is HER2-receptor-less. Triple-negative breast cancer treatment options, Estrogen receptor (ER) and progesterone receptor (PR) positive breast cancer can be treated with hormone therapy. Breast cancer with an excessive amount of HER2 can be treated with anti-HER2 drugs such as trastuzumab. In women with triple-negative breast cancer, malignant cells do not contain estrogen, progesterone or HER2 receptors. Breast cancer, ER, PR and, HER2-negative, cannot be treated with drugs (such as trastuzumab) that act by blocking hormone therapy or HER2. Fortunately, triple-negative breast cancer can be treated with other drugs such as chemotherapy, radiotherapy and non-HER2 target therapy.

Triple Negative Breast Cancer Treatment

Triple negative breast cancer does not express estrogen receptor, progesterone receptor, or human epithelial growth factor receptor 2 (HER2). This particular subtype is particularly common in BRCA1 mutant carriers (80% or more) and over-expressed in pre-menopausal and African women. About 15% to 20% of breast cancer is triple negative. "Our understanding over the past few years has been greatly improved, and our clinical and translation studies have been promoted by a mental treatise 1 suggesting that there are different subtypes within the subtypes of triple-negative breast cancer.

New Treatment For Triple Negative Breast Cancer
The president of the previous United States Cancer Society (AACR), executive director of the Fred Hutchinson Cancer Institute, Seattle Cancer Care Alliance, University of Washington School of Medicine, Department of Oncology. AACR International Conference on New Frontiers in Cancer Research in Cape Town, South Africa Important information in the treatment of four of the four subtypes of the six subtypes of triple-negative bosom tumor distinguished by the quality articulation cluster were analyzed: basal-like 1 and 2 subtypes.

Includes immune-regulating subtypes and lumen-type androgen receptor subtypes. Basic 1 and 2 sub-types of preoperative carboplatin and angiogenesis inhibitors in three negative breast cancers were examined for the effect of bevacizumab (Avastin). In this test, the addition of bevacizumab was significantly increased (in United States, Cancer and Leukemia group B 40603 [Alliance] breast is a pathological complete response, but does not react in the axillary. It also brought more side effects. Dr. Davidson concluded that the use of this drug is not really appropriate in the context of this multimodal chemotherapy.

"As a result of this trial or any other, bevacizumab fell off the radar as a form of treatment for breast cancer any stage. But the addition of carboplatin was more promising, she noted. Carboplatin increased pathological full response in the breast and axillary, and the side effects were typically expected from chemotherapy.

"This trial makes us more aggressive in the context of the management of breast cancer in this particular type of platinum, " she said. Taki is also an active drug of breast cancer. In phase III test of carboplatin vs. BRCA1 in 3-negative or 2-positive metastatic breast cancer (TNT test), the three reproductive lineage BRCA mutation carriers Although the response rate for carboplatin was much better than the carboplatin and the de-paracetamol were equally effective. ( Triple negative breast cancer treatment ) This test was important because it examined the clinical outcomes in the situation of BRCA reproductive sequence state, homologous recombination failure assay, BRCA1 methylation state, and BRCA1 mRNA silencing.

"In this study, it is clear that the mutation state of the germ cell system BRCA is very important in determining the reaction to chemotherapy," Dr. Davidson said. Also, in this trial, the homologous recombinant failure assay of biology or "BRCA", which may be similar to the BRCA mutation, was not useful in distinguishing the response to any of the drugs. The response to the chemotherapy agent seems to be different depending on how the BRCA gene is inactivated. "If inactivated for BRCA methylation, the result will be one, but if silencing is the cause, another result will be obtained," she explains. "I withdraw this because the means by which these genes are inactivated are obviously biologically different and may have meaningful clinical significance" in the Stage II Examination of cisplatin or carboplatin of tbcrc009 metastatic triple-negative breast cancer The total response rate of all 86 cases was 25.6%, cisplatin (32.6%) and BRCA1/2 mutations (54.5%).

New treatment for triple negative breast cancer - "This data is platinum really this sub-type activator of breast cancer," Dr. Davidson said. The DNA restoration pathway is also an important target of treatment in this setting. BRCA1/2 and "BRCA-like" triple-negative breast cancer can be helpless against poly ADP-Ribose Polymerase (PARP) restraint. Parp is a sound focus of treatment in an assortment of settings, including here, she said. In United States, the two PARP inhibitors Ola Rib (olaparib) (Lynparza) and Luke Rib (Rubraca) is at present endorsed as a restorative operator for BRCA1/2-positive ovarian cancer. (another PARP inhibitor, leek rib [Zejula] has been endorsed as a treatment for intermittent ovarian cancer, paying little mind to the province of BRCA.